CA
MYGN icon

Clearstead Advisors’s Myriad Genetics MYGN Stock Holding History

Clearstead Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36K Buy
+238
New +$1.08K ﹤0.01% 2608
2026
Q1 		– Sell
-59
Closed -$363 – 2637
2025
Q4 		$363 Sell
59
-1,241
-95% -$9K ﹤0.01% 2344
2025
Q3 		$9.4K Buy
1,300
+424
+48% +$2.52K ﹤0.01% 1949
2025
Q2 		$4.65K Buy
+876
New +$5.17K ﹤0.01% 2125

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors's MYGN Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Myriad Genetics (MYGN) in Q2 2026: 238 shares worth $1.36K. The stake represents ﹤0.01% of the portfolio and ranks #2608 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in MYGN as recently as Q4 2025.

Clearstead Advisors first reported a position in MYGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.4K in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Clearstead Advisors held 238 shares of Myriad Genetics worth $1.36K as of Q2 2026.
  • Myriad Genetics was a new Clearstead Advisors position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2608 holding.
  • Clearstead Advisors first reported a position in Myriad Genetics in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Myriad Genetics position peaked at $9.4K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.